FIG 7.

Fumarate-mediated potentiation observed in the presence of CF patient sputum. The PAO1 laboratory and the CF patient isolate 10004 were tested. Plots of percent survival versus TOB concentration in the PSP assay in the presence of 10% sputum purified through filtration are shown for PAO1 with early sputum from patient 1 (A), for PAO1 with early sputum from patient 2 (B), for PAO1 with late sputum from patient 2 (C), and for clinical isolate 10004 with late sputum from patient 2 (D). Early sputum refers to pre-antibiotic treatment for the most recent exacerbation, while late refers to posttreatment. Values of percent survival depict the mean ± SD (n = 2).